Celadon Pharmaceuticals Regulatory News (CEL)

1 Apr 2005 07:00

Celsis International PLC01 April 2005 CELSIS INTERNATIONAL PLC PERIOD END TRADING UPDATE 1 April 2005: Celsis International plc ("Celsis" or the "Company"), the rapidmicrobial detection and analytical services company, today announces an updateon trading prior to the close of its financial year. The Group has made good progress in the second half of the year, building on thesuccessful first half year performance. The Product Group continues to performwell across all of its market segments, with the Laboratory Group havingrebounded during the first half of the year. As a result, the company is ontrack to perform in line with market expectations for the year ended 31 March2005. Celsis will announce its preliminary results for the year ended 31 March 2005,on Tuesday 24 May 2005. There will be a presentation to analysts on the day at9.30am, held at Financial Dynamics, Holborn Gate, 26 Southampton Buildings,London, WC2A 1PB. Jay LeCoque, Chief Executive Officer, of Celsis International plc commented: "I am pleased to report that Celsis has continued to see robust trading thisfinancial year and is set to report year end results in line with expectations.Celsis continues to secure new growth across all of its market segments and isstrengthening its position as the leading supplier in our respective industries. Celsis remains a profitable and cash generative company. We are optimisticabout Celsis' prospects and look forward to announcing further news in the nearfuture." Enquiries: Celsis International plc Tel: 01638 600 151 Jay LeCoque, Chief Executive Officer Jenny Parsons, Corporate Communications Financial Dynamics Tel: 020 7831 3113 Ben Atwell Lucy Briggs Notes to editors Celsis International plc Celsis International plc is a microbial detection and analytical servicescompany operating through two divisions, the Product Group and the LaboratoryGroup. Using its proprietary enzyme technology, the Product Group is the world leaderin the provision of diagnostic systems for the rapid detection of microbialcontamination. It works in close collaboration with many of the world's leadingpharmaceutical, personal care and beverage companies, ensuring the safety andquality of products bound for consumers. The Laboratory Group providesoutsourced analytical testing services to pharmaceutical companies to ensure thestability and chemical composition of their products. In addition to ensuring product quality and safety for consumers, both divisionshave the capacity to deliver substantial cost savings to Celsis' customers. Byreducing the time it takes to test and release raw materials and finished goodsto the market place, Celsis' products facilitate increased manufacturingproductivity and improved supply chain management. Celsis International plc is listed on the London Stock Exchange (CEL.L).Further information can be found on the Company's website at www.celsis.com. This information is provided by RNS The company news service from the London Stock Exchange